The next 10 years in the management of peripheral artery disease: Perspectives from the 'PAD 2009' conference

European Journal of Vascular and Endovascular Surgery

Volumn 40, Issue 3, 2010, Pages 375-380

  Norgren, L ^a   Hiatt, W R ^b   Dormandy, J A ^c   Hirsch, A T ^d   Jaff, M R ^e   Diehm, C ^f   Baumgartner, I ^g   Belch, J J F ^h  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF COLORADO   (United States)

^c ST GEORGE S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF MINNESOTA   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g BERN UNIVERSITY HOSPITAL   (Switzerland)

^h UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Guidelines; Information; Peripheral artery disease; Research

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST BENEFIT ANALYSIS; HEALTH CARE SYSTEM; MEDICAL INFORMATION; MEDICAL RESEARCH; MEDICAL SPECIALIST; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK MANAGEMENT;

EID: 84859165378     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2010.05.005     Document Type: Article

References (29)

1. Hirsch AT, Murphy TP, Lovell MB, Twillman G, Treat-Jacobsen D, Harwood EM, et al. Gaps in public knowledge of peripheral arterial disease; the first national PAD public awareness survey. Circulation 2007;116:2086-94. (Pubitemid 350023753)
2. Lovell M, Harris K, Forbes T, Twillman G, Abramson B, et alOn behalf of the peripheral arterial disease Coalition. Peripheral arterial disease: Lack of awareness in Canada. Canadian J Cardiol 2009;25(1):39-45.
3. McDermott MM, Guralnik JM, Ferrucci L, Tian L, Liu K, Liao Y, et al. Asymptomatic peripheral arterial disease is associated with more adverse lower extremity characteristics than intermittent claudication. Circulation 2008;117:2484-91. (Pubitemid 351670455)
4. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). Circulation 2006;113:-463e-465.
5. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR. Inter-Society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007;33:S1eS70.
6. Scottish Intercollegiate Guidelines Network. Diagnosis and management of peripheral arterial disease. A national clinical guideline, www.sign.ac.uk; 2006.
7. Belch J, Stansby G, Target PAD. Peripheral arterial disease: Still on the periphery? BMJ 2006;532:1213. (Pubitemid 44365462)
8. Hirsch AT, Gloviczki P, Drooz A, Lovell M, Creager MA. Special communication mandate for creation of a national peripheral arterial disease awareness program: An opportunity to improve cardiovascular health. Angiology 2004;55:233-42.
9. Hirsch AT, Hartman L, Town RJ, Virnig BA. National healthcare costs of peripheral arterial disease in the USA medicare population. Vasc Med 2008;13:209-15.
10. Mahoney EM, Wang K, Cohen DJ, Hirsch AT, Alberts MJ, Eagle K, et al. One-year costs associated with vascular hospitalizations and chronic medication use in patients with or at risk of atherothrombosis in the United States. Circulation-Cardiovascular Quality and Outcomes 2008;1:38-45.
11. Flu H, van der Hage JH, Knippenberg B, Merkus JW, Hamming JF, Lardenoye JW. Treatment for peripheral arterial obstructive disease: An appraisal of the economic outcome of complications. J Vasc Surg 2008;48:368-76.
12. US Preventive Services TaSK Force. Using non-traditional risk factors in coronary heart disease risk assessment: US preventive services task force recommendation statement. Ann Intern Med 2009;151:474482.
13. Mayor S. Report gives snapshot health research funding in the UK. BMJ 2006;332:1230.
14. Cooper C, Murphy T, Matsumoto A, Steffes M, Cohen D, Jaff MR, et al. Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: Rationale and design of the CORAL trial. Am Heart J 2006;152:59-66. (Pubitemid 43974724)
15. Murphy TP, Hirsch AT, Ricotta JJ, Cutlip DE, Mohler E, Regensteiner JG, et alon behalf of the CLEVER Steering Committee. The National Institutes of Health CLEVER Study (Claudication: Exercise vs. endoluminal revascularization): Rationale and methods. J Vasc Surg 2008;47:1356-63.
16. Iglehart J. Prioritizing comparative-effectiveness research-IOM recommendations. N Engl J Med 2009;361:325-8.
17. Attanasio S, Snell J. Therapeutic angiogenesis in the management of critical limb ischemia. Cardiology 2009;17:115-20. in Review.
18. Kalka C, Baumgartner I. Gene and stem cell therapy in peripheral arterial occlusive disease. Vasc Med 2008;13: 157-72. (Pubitemid 351954349)
19. De Haro J, Acin F, Lopez-Quintana A, Florez A, Martinez-Aguilar E, Varela C. Metaanalysis of randomized controlled clinical trials in angiogenesis: Gene and cell therapy in peripheral arterial disease. Heart Vessels 2009;24:321-8.
20. Mohler 3rd ER, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003;108: 1481-6. (Pubitemid 37176455)
21. O'Donnell ME, Badger SA, Sharif MA, Makar RR, McEneny J, Young IS, et al. The effects of cilostazol on exercise-induced ischemia-reperfusion injury in patients with peripheral arterial disease. Eur J Vasc Endovasc Surg 2009;37:326-35.
22. Stoner MC, deFreitas DJ, Manwaring MM, Carter JJ, Parker FM, Powell CS. Cost per day of patency: Understanding the impact of patency and reintervention in a sustainable model of health care. J Vasc Surg 2008;48:1489-96.
23. Greenhalgh RM, Belch JJ, Brown LC, Gaines PA, Gao L, Reise JA, et al. The adjuvant benefit of angioplasty in patients with mild to moderate intermittent claudication (MIMIC) managed by supervised exercise, smoking cessation advice and best medical therapy: Results from two randomised trials for stenotic femoropopliteal and aortoiliac arterial disease. Eur J Vasc Endovasc Surg 2008;36:680-8.
24. Spronk S, Bosch JL, den Hoed PT, Veen HF, Pattynama PM, Hunink MG. Cost-effectiveness of endovascular revascularization compared to supervised hospital-based exercise training in patients with intermittent claudication: A randomized controlled trial. J Vasc Surg 2008;48:1472-80.
25. deVries SO, Visser K, deVries JA, Wong JB, Donaldson MC, Hunink MG. Intermittent claudication: Cost-effectiveness of revascularization versus exercise therapy. Radiology 2002;222: 25-36. (Pubitemid 34031460)
26. Singh S, Evans L, Datta D, Gaines P, Beard JD. The costs of managing lower limb-threatening ischaemia. Eur J Vasc Endovasc Surg 1996;12:359-62. (Pubitemid 26379154)
27. Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): Multicentre, randomised controlled trial. Lancet 2005; 366:1925-34. (Pubitemid 41713982)
28. Michael CS, Dorian JD, Mark MM, Jacqueline JC, Frank MP, Powell CS. Cost per day of patency: Understanding the impact of patency and reintervention in a sustainable model of health care. J Vasc Surg 2008;48:1489-96.
29. Labs KH, Dormandy JA, Jaeger KA, Stuerzebecher CS, Hiatt WR. Transatlantic conference on clinical trial guidelines in peripheral arterial disease. Circulation 1999;100:-75e-81.